Loading...

Amarin

Nasdaq:AMRN
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AMRN
Nasdaq
$6B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
AMRN Share Price and Events
7 Day Returns
-4.9%
NasdaqGM:AMRN
-3.3%
US Pharmaceuticals
-0.3%
US Market
1 Year Returns
514.3%
NasdaqGM:AMRN
7.1%
US Pharmaceuticals
7%
US Market
AMRN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Amarin (AMRN) -4.9% 3.1% 4.8% 514.3% 860.6% 1039.4%
US Pharmaceuticals -3.3% -6% -2% 7.1% 5.1% 14.4%
US Market -0.3% 2% 8.5% 7% 37.7% 46.8%
1 Year Return vs Industry and Market
  • AMRN outperformed the Pharmaceuticals industry which returned 7.1% over the past year.
  • AMRN outperformed the Market in United States of America which returned 7% over the past year.
Price Volatility
AMRN
Industry
5yr Volatility vs Market
Related Companies

AMRN Value

 Is Amarin undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Amarin to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Amarin.

NasdaqGM:AMRN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:AMRN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 7.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.674 (1 + (1- 12.5%) (1.35%))
0.787
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 7.14%)
8.44%

Discounted Cash Flow Calculation for NasdaqGM:AMRN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Amarin is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:AMRN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.44%)
2019 70.40 Analyst x1 64.92
2020 245.95 Analyst x2 209.15
2021 467.95 Analyst x2 366.95
2022 888.65 Analyst x2 642.60
2023 909.50 Analyst x1 606.48
2024 931.72 Est @ 2.44% 572.93
2025 955.29 Est @ 2.53% 541.69
2026 980.03 Est @ 2.59% 512.46
2027 1,005.82 Est @ 2.63% 485.00
2028 1,032.59 Est @ 2.66% 459.15
Present value of next 10 years cash flows $4,461.32
NasdaqGM:AMRN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,032.59 × (1 + 2.73%) ÷ (8.44% – 2.73%)
$18,571.00
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $18,571.00 ÷ (1 + 8.44%)10
$8,257.72
NasdaqGM:AMRN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,461.32 + $8,257.72
$12,719.04
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $12,719.04 / 330.64
$38.47
NasdaqGM:AMRN Discount to Share Price
Calculation Result
Value per share (USD) From above. $38.47
Current discount Discount to share price of $18.06
= -1 x ($18.06 - $38.47) / $38.47
53.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Amarin is available for.
Intrinsic value
>50%
Share price is $18.06 vs Future cash flow value of $38.47
Current Discount Checks
For Amarin to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Amarin's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Amarin's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Amarin's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Amarin's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:AMRN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.39
NasdaqGM:AMRN Share Price ** NasdaqGM (2019-04-18) in USD $18.06
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.42x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Amarin.

NasdaqGM:AMRN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AMRN Share Price ÷ EPS (both in USD)

= 18.06 ÷ -0.39

-46.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amarin is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Amarin is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Amarin's expected growth come at a high price?
Raw Data
NasdaqGM:AMRN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -46.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
59%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.5x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Amarin, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Amarin's assets?
Raw Data
NasdaqGM:AMRN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.40
NasdaqGM:AMRN Share Price * NasdaqGM (2019-04-18) in USD $18.06
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 3.44x
United States of America Market PB Ratio Median Figure of 5,184 Publicly-Listed Companies 1.91x
NasdaqGM:AMRN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AMRN Share Price ÷ Book Value per Share (both in USD)

= 18.06 ÷ 0.40

45.1x

* Primary Listing of Amarin.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amarin is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Amarin's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Amarin has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AMRN Future Performance

 How is Amarin expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
59%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Amarin expected to grow at an attractive rate?
  • Amarin's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Amarin's earnings growth is expected to exceed the United States of America market average.
  • Amarin's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:AMRN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:AMRN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 59%
NasdaqGM:AMRN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 33.8%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:AMRN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:AMRN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,539 565 1,209 3
2022-12-31 1,204 410 758 3
2021-12-31 867 263 353 3
2020-12-31 567 103 84 4
2019-12-31 365 -44 -44 4
NasdaqGM:AMRN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 229 -95 -116
2018-09-30 206 -65 -105
2018-06-30 198 -43 -92
2018-03-31 190 -29 -71
2017-12-31 181 -33 -68
2017-09-30 166 -50 -73
2017-06-30 151 -62 -78
2017-03-31 139 -61 -78
2016-12-31 130 -72 -86
2016-09-30 118 -76 -81
2016-06-30 107 -80 -97
2016-03-31 91 -96 -147

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Amarin's earnings are expected to grow significantly at over 20% yearly.
  • Amarin's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:AMRN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Amarin Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AMRN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.98 3.63 2.33 2.00
2022-12-31 1.97 2.30 1.63 2.00
2021-12-31 1.09 1.25 0.93 3.00
2020-12-31 0.26 0.37 0.13 4.00
2019-12-31 -0.17 -0.09 -0.25 5.00
NasdaqGM:AMRN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.39
2018-09-30 -0.37
2018-06-30 -0.33
2018-03-31 -0.26
2017-12-31 -0.25
2017-09-30 -0.27
2017-06-30 -0.31
2017-03-31 -0.33
2016-12-31 -0.41
2016-09-30 -0.42
2016-06-30 -0.53
2016-03-31 -0.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Amarin will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Amarin's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Amarin has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AMRN Past Performance

  How has Amarin performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Amarin's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Amarin does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Amarin's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Amarin's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Amarin's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Amarin Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AMRN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 229.21 -116.45 227.00 55.90
2018-09-30 205.75 -105.24 182.95 55.94
2018-06-30 197.79 -91.60 166.18 52.56
2018-03-31 190.39 -71.02 143.79 48.10
2017-12-31 181.10 -67.87 134.55 47.16
2017-09-30 165.93 -72.85 130.14 45.39
2017-06-30 151.31 -77.80 123.00 48.18
2017-03-31 139.18 -77.52 117.52 47.07
2016-12-31 130.08 -86.35 111.37 49.98
2016-09-30 118.02 -80.79 103.67 53.15
2016-06-30 106.77 -97.34 104.33 52.75
2016-03-31 91.37 -146.84 104.32 52.18
2015-12-31 81.76 -149.06 101.04 51.06
2015-09-30 71.60 -146.83 95.92 50.15
2015-06-30 64.27 -140.55 88.46 51.52
2015-03-31 59.17 -62.38 83.50 51.23
2014-12-31 54.20 -56.36 79.35 50.33
2014-09-30 47.83 -52.12 80.69 52.46
2014-06-30 42.08 -74.95 89.70 54.83
2014-03-31 34.98 -130.05 102.56 60.59
2013-12-31 26.35 -166.23 121.25 72.75
2013-09-30 16.25 -161.38 118.24 75.37
2013-06-30 7.84 -138.93 103.36 79.46
2013-03-31 2.34 -153.06 83.03 76.04
2012-12-31 -179.18 57.79 58.96
2012-09-30 -150.28 47.43 45.69
2012-06-30 -27.51 37.47 30.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Amarin has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Amarin has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Amarin improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Amarin's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Amarin has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AMRN Health

 How is Amarin's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Amarin's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Amarin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Amarin's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Amarin's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Amarin Company Filings, last reported 3 months ago.

NasdaqGM:AMRN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 152.33 80.35 249.23
2018-09-30 -52.83 113.43 81.89
2018-06-30 -46.69 117.02 102.26
2018-03-31 -16.66 119.12 129.05
2017-12-31 -65.10 122.66 73.64
2017-09-30 -46.11 124.91 79.09
2017-06-30 -38.76 127.46 85.46
2017-03-31 -28.77 128.43 96.08
2016-12-31 -9.06 116.45 98.25
2016-09-30 15.18 117.39 117.56
2016-06-30 -164.42 246.61 72.49
2016-03-31 -156.14 243.45 81.36
2015-12-31 -127.55 242.99 106.96
2015-09-30 -111.09 231.11 118.98
2015-06-30 -91.35 230.56 136.05
2015-03-31 -61.82 227.38 161.20
2014-12-31 -88.45 226.86 119.54
2014-09-30 -69.24 223.43 135.44
2014-06-30 -49.98 207.87 150.53
2014-03-31 -57.59 245.81 164.28
2013-12-31 -33.86 250.01 191.51
2013-09-30 -17.70 239.84 225.89
2013-06-30 -94.33 236.74 149.43
2013-03-31 -60.09 239.21 201.78
2012-12-31 -4.00 233.98 260.24
2012-09-30 0.04 130.78 215.11
2012-06-30 5.32 127.44 250.26
  • Amarin's level of debt (52.7%) compared to net worth is high (greater than 40%).
  • Amarin had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Amarin has sufficient cash runway for 2.6 years based on current free cash flow.
  • Amarin has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -16% each year.
X
Financial health checks
We assess Amarin's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Amarin has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AMRN Dividends

 What is Amarin's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Amarin dividends. Estimated to be 0% next year.
If you bought $2,000 of Amarin shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Amarin's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Amarin's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:AMRN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:AMRN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Amarin has not reported any payouts.
  • Unable to verify if Amarin's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Amarin's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Amarin has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Amarin's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Amarin's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Amarin afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Amarin has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AMRN Management

 What is the CEO of Amarin's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Thero
COMPENSATION $3,408,176
AGE 57
TENURE AS CEO 5.3 years
CEO Bio

Mr. John F. Thero has been the Chief Executive Officer of Amarin Corporation Plc since January 1, 2014 and has been its President since November 2010. Mr. Thero serves as the President of U.S. at Amarin Corporation plc. Mr. Thero served as the Chief Financial Officer of Amarin Corporation plc since November 2009 to November 2011 and served as its Chief Accounting Officer and Assistant Secretary. Mr. Thero has more than 20 years of senior financial and operational management experience including over 15 years supporting the growth of life science companies. He served as the Chief Financial Officer and Senior Vice President of Finance at ViaCell, Inc. since July 2, 2007 and its Senior Vice President of Business Operations. Mr. Thero served as a Senior Vice President of Finance , Treasurer and the Chief Financial Officer at Acusphere, Inc. from February 2003 to June 30, 2007 and served as its Principal Accounting Officer & Secretary until June 30, 2007. He also served as a Senior Vice President of Administration of Acusphere, Inc. since February 2003. He served as a Senior Vice President of Finance, Treasurer and the Chief Financial Officer of ABIOMED, Inc. from 1994 to January 9, 2003. From 1992 to 1994, he served as the Chief Financial Officer and Acting President of the restructuring of two venture-backed companies. Mr. Thero began his professional career at Arthur Andersen LLP. From 1987 to 1992, he served as the Chief Financial Officer of Aries Technology, Inc. From 1983 to 1987 he also served at the Commercial Audit Division of Arthur Andersen LLP. He has been a Director of Amarin Corporation Plc since January 1, 2014 and Chiasma, Inc. since November 30, 2015. He became a Certified Public Accountant in 1987. Mr. Thero received a B.A. in Economics and Accounting from The College of the Holy Cross.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Amarin management team in years:

3.3
Average Tenure
53
Average Age
  • The tenure for the Amarin management team is about average.
Management Team

John Thero

TITLE
President
COMPENSATION
$3M
AGE
57
TENURE
5.3 yrs

Mike Kalb

TITLE
CFO, Senior VP & Assistant Secretary
COMPENSATION
$1M
AGE
47
TENURE
2.8 yrs

Steve Ketchum

TITLE
President of Research & Development
COMPENSATION
$1M
AGE
53
TENURE
3.3 yrs

Joe Kennedy

TITLE
Executive VP
COMPENSATION
$1M
AGE
50
TENURE
7.3 yrs

Elisabeth Schwartz

TITLE
Senior Director of Investor Relations

Dan Dunham

TITLE
Senior VP & Chief Commercial Compliance Officer
TENURE
0.5 yrs

Rami Daoud

TITLE
Senior Vice President of Corporate Development
TENURE
3.3 yrs

Donna Pasek

TITLE
Vice President of Human Resources
TENURE
5.7 yrs

Keith Wood

TITLE
Head of Research and Development Operations
TENURE
11.3 yrs

Aaron Berg

TITLE
Senior VP & Chief Commercial Officer
AGE
55
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Amarin board of directors in years:

9.2
Average Tenure
68
Average Age
  • The tenure for the Amarin board of directors is about average.
Board of Directors

Lars Ekman

TITLE
Chairman & Lead Independent Director
COMPENSATION
$210K
AGE
68
TENURE
5.3 yrs

John Thero

TITLE
President
COMPENSATION
$3M
AGE
57
TENURE
5.3 yrs

John Climax

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
$39K
AGE
65
TENURE
12.9 yrs

Paddy O'Sullivan

TITLE
Non-Executive Director
COMPENSATION
$165K
AGE
76
TENURE
7.3 yrs

Dave Stack

TITLE
Non-Executive Independent Director
COMPENSATION
$160K
AGE
68
TENURE
6.3 yrs

Jan Wallace

TITLE
Member of Scientific Advisory Board
AGE
77
TENURE
12.9 yrs

Mark Pierce

TITLE
Member of the Scientific Advisory Board
TENURE
12.9 yrs

Reid Patterson

TITLE
Member of the Scientific Advisory Board
TENURE
12.9 yrs

Joe Zakrzewski

TITLE
Non-Executive Director
COMPENSATION
$150K
AGE
56
TENURE
9.3 yrs

G. van Heek

TITLE
Independent Non-Executive Director
COMPENSATION
$173K
AGE
68
TENURE
9.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Amarin's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Amarin has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AMRN News

Simply Wall St News

Amarin Corporation plc (NASDAQ:AMRN): When Will It Breakeven?

Amarin Corporation plc's (NASDAQ:AMRN):. … Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. … Many investors are wondering the rate at which AMRN will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

What does Amarin Corporation plc's (NASDAQ:AMRN) Balance Sheet Tell Us About Its Future?

Let’s take a look at AMRN’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Note that this information is centred entirely on financial health and is a top-level understanding, so I encourage you to look further. … AMRN’s Debt (And Cash Flows)

Simply Wall St -

Announcing: Amarin Stock Rocketed An Astounding 1359% In The Last Three Years

Amarin isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Shareholders of unprofitable companies usually expect strong revenue growth. … It's always tempting to take profits after a share price gain like that, but high-growth companies like Amarin can sometimes sustain strong growth for many years.

Simply Wall St -

How Much Of Amarin Corporation plc (NASDAQ:AMRN) Do Institutions Own?

Companies of this size are usually well known to retail investors, too. … Taking a look at the our data on the ownership groups (below), it's seems that. … We can zoom in on the different ownership groups, to learn more about AMRN

Simply Wall St -

An Intrinsic Calculation For Amarin Corporation plc (NASDAQ:AMRN) Shows It's 34.97% Undervalued

by projecting its future cash flows and then discounting them to today's value. … Discounted Cash Flows (DCF). … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

Amarin Corporation plc's (NASDAQ:AMRN) Path To Profitability

Amarin Corporation plc's (NASDAQ:AMRN):. … Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. … The company’s loss has recently broadened since it announced a -US$67.9m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$105.2m, moving it further away from breakeven.

Simply Wall St -

Does Amarin Corporation plc's (NASDAQ:AMRN) CEO Salary Reflect Performance?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does John Thero's Compensation Compare With Similar Sized Companies. … Most shareholders would consider it a positive that John Thero takes less compensation than the CEOs of most similar size companies, leaving more for shareholders.

Simply Wall St -

Analysts Expect Breakeven For Amarin Corporation plc (NASDAQ:AMRN)

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. … With the latest financial year loss of -US$67.86m and a trailing-twelve month of -US$71.02m, the US$719.28m market-cap amplifies its loss by moving further away from its breakeven target. … Many investors are wondering the rate at which AMRN will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Investors Are Undervaluing Amarin Corporation plc (NASDAQ:AMRN) By 26.89%

Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Amarin Corporation plc (NASDAQ:AMRN) as an investment opportunity. … by projecting its future cash flows and then discounting them to today's value. … If you are reading this and its not June 2018 then I highly recommend you check out the latest calculation for Amarin by following the link below.

Simply Wall St -

AMRN Company Info

Description

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Biologix FZCo, and HLS Therapeutics, Inc. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Details
Name: Amarin Corporation plc
AMRN
Exchange: NasdaqGM
Founded: 1989
$5,971,363,763
330,640,297
Website: http://www.amarincorp.com
Address: Amarin Corporation plc
2 Pembroke House,
Upper Pembroke Street 28-32,
Dublin,
Co. Dublin, 2,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AMRN ADR EACH REP 1 ORD GBP0.50 Nasdaq Global Market US USD 01. Apr 1993
DB EH3A ADR EACH REP 1 ORD GBP0.50 Deutsche Boerse AG DE EUR 01. Apr 1993
Number of employees
Current staff
Staff numbers
530
Amarin employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 23:31
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.